AveXis (AVXS) Stock Price, News & Analysis

Company Overview

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.

Key Stats

• Today's Range: $217.83 to $217.83
• 50-Day Range: N/A
• 52-Week Range: $65.54 to $217.94
• Volume: 222 shs
• Average Volume: 816,305 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AVXS Stock Analysis - Frequently Asked Questions

How were AveXis' earnings last quarter?

AveXis, Inc. (NASDAQ:AVXS) issued its earnings results on Wednesday, May, 9th. The company reported ($6.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.32) by $2.88.

When did AveXis IPO?

AveXis (AVXS) raised $86 million in an initial public offering on Thursday, February 11th 2016. The company issued 4,300,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers.

What other stocks do shareholders of AveXis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AveXis investors own include REGENXBIO (RGNX), bluebird bio (BLUE), Bristol-Myers Squibb (BMY), Exelixis (EXEL), Mallinckrodt (MNK), AbbVie (ABBV) and BioLife Solutions (BLFS).

Company Calendar

• Last Earnings: 5/09/2018
• Today: 6/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AVXS
• CIK: 1652923
• Web: www.avexis.com
• Phone: 847-572-8280
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A